Pilot Study of Paxman Scalp Cooling to Prevent Hair Loss in Children and Young Adults Receiving Chemotherapy for Non-Cancerous Conditions and Solid Tumors

What this Trial Is About

This research aims to evaluate whether the Paxman scalp cooling device can prevent hair loss in children and young adults receiving chemotherapy for non-cancerous conditions or solid tumors. The study focuses on assessing the safety and feasibility of scalp cooling in these patients and explores how often and how severe chemotherapy-induced hair loss occurs when using the cooling device. Participants will receive scalp cooling starting 30 to 45 minutes before each chemotherapy session, with the cooling maintained throughout the drug infusion and continuing for 120 to 180 minutes afterward. A trained staff member will apply, monitor, and remove the cooling cap, ensuring the scalp temperature stays at about 3C 37F. The therapy will be provided with every chemotherapy dose, following the manufacturers instructions. During the study, participants will have photographs taken to assess hair loss, with additional photos for those with solid tumors after every two chemotherapy cycles. They will also complete questionnaires about symptoms and tolerability at different points, including baseline, during treatment, and follow-ups. Safety and feasibility will be closely monitored up to two years, and study involvement will last according to the chemotherapy schedule and follow-up assessments.

Study Of Cold Cap Therapy For Prevention of Hairloss in Pediatric Patients Receiving Chemotherapy For Non-Malignant Indications and Solid Tumors